Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The clinical value of drug litigation

Executive Summary

Litigation against pharma companies can result in better definition of drug risks, Harvard University Medical School's Aaron Kesselheim and Jerry Avorn argue in a Jan. 17 JAMA article. In several cases involving SSRIs and COX-2s, lawsuits produced useful data that previously had not been publicly released, the authors say. Suits could also motivate "proper disclosure initially by presenting the possibility of substantial damages in cases of misconduct." Describing litigants as "drug safety researchers of last resort," the essay criticizes FDA's effort to pre-empt product liability claims (1"The Pink Sheet" Aug. 28, 2006, p. 7)...

You may also be interested in...

Court Ruling On Preemption Leaves Window Open For False Advertising Suits

FDA's failure to include false advertising claims in its policy on preemption implies that the agency "does not intend its review of promotional materials to preempt false advertising claims," according to a recent federal court decision

European SEAC Opinion Unchanged: Microplastics Must Be Out Of All Cosmetics Within Six Years

The final opinion of ECHA’s Socio-Economic Analysis Committee, published on 1 March, is largely unchanged from its July 2020 draft opinion with regard to microplastic in cosmetic products. That means industry may have to convince EU member state authorities that the restriction proposal has a serious proportionality problem.

QUOTED. 2 March 2021. Michael Coyle.

Representatives from cardiac monitoring device manufacturers and professional societies are working together to persuade Medicare carrier Novitas to reconsider its payment rates for extended cardiac monitoring. See what Michael Coyle, iRhythm’s CEO, said about it here.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts